O’Neil Health Care Weekly

XLV gained 101bps last week and is now testing resistance between $141.77 and $143.42 (all-time highs). Look for support at the
rising 21-DMA ($137.39). Its RS line is consolidating a strong move from lows constructively, warranting an equal-to-overweight
sector positioning.

Market View

The U.S. market remains in an Uptrend Under Pressure. The S&P 500 bounced off support at its 21-DMA (4,724) and is retesting 52-week highs (4,793). The Nasdaq held above price support (14,446) at the top of the prior base consolidation, which coincides with July highs and has regained its 21-DMA (14,770). The distribution day count stands at five and three, respectively.

O’Neil Health Care Weekly

XLV gained over 2% last week, strongly outperforming the broader index on the back of larger cap defensive ideas across Pharma
(PPH). ABBV, AMGN, GSK, LLY, MRK, and NVS have rallied sharply to start the year with many breaking out. Managed Care also
caught an early bid with most ideas including UNH (reporting Friday morning), CI, and MOH moving back on the right side of bases.
Though positive to see Health Care outperform, the majority of larger cap pharma are long-term rangebound ideas that we would not
chase at pivot points. This week, the JPM conference takes place with multiple companies already pre-announcing numbers this
morning including DXCM. BSX also announced the acquisition of AXNX, an idea we highlighted last week. We would remain focused
on higher growth areas of the sector including Biotech (XBI) and Med Devices (IHI) which are recovering from last year’s severe
decline. Given XLV now has a rising RS line, we now recommend an equal-to overweight sector positioning.

HealthCare Conference

Key points from this report:

  • Ideas are showing positive technical trends, holding above key price and/or moving average support.
  • Ideas also have positive fundamental ratings and rankings and/or accelerating annual EPS growth.
  • Included are 17 annotated charts.

Market View

U.S. market was shifted to an Uptrend Under Pressure. Indices pulled back off highs on rising distribution. The S&P 500 is
testing its 21-DMA (4,692) while the Nasdaq breached this short-term moving average (14,673). The next level of support is near the
July 2023 high (4,607/14,447), followed by the 50-DMA (4,540/14,162). The distribution day count stands at six and four, respectively.

O’Neil Health Care Weekly

XLV rallied 101bps last week in very low volume and is now testing heavy resistance between $136 and $137. Should a
pullback occur, look for support at the rising 21-DMA ($133.77). Its RS line has started to rise, but has yet to make a
higher high, warranting an equal-weight sector positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. S&P 500 advanced for a ninth consecutive week, gaining 0.3%, while the Nasdaq paused after eight weeks of gains, trading just slightly lower. Immediate support for the indices is seen along their respective 10-DMA (4,754/14,975), followed by the 21-DMA (4,686/14,714). The S&P 500 has resistance near January 2022 high of ~4,800, while the Nasdaq has resistance near the 15,320 level. Indices each picked up a fourth distribution day on Friday. The distribution day count for both indices is four, with one set to expire on the S&P 500 next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq rose for the eighth consecutive week despite
briefly pulling back and testing support at the 10-DMA (4,707/14,787). The S&P 500 is approaching resistance near ~4,800 (+1%) or
all-time highs, while the Nasdaq is testing resistance near the 15,320 (+2%) level. The distribution day count for both indices remains
at three.